RxSight Inc (NASDAQ:RXST) shares are roughly flat following earlier weakness during Thursday's session after the company announced pricing of its $100 million proposed public offering of common stock.

The company plans to sell 1,785,714 shares of common stock at $56.00 per share, with an option for underwriters to purchase an additional 267,857 shares. Gross proceeds are estimated at around $100 million. The offering is expected to close on May 13.

BofA Securities is the lead bookrunning manager, with J.P. Morgan as a bookrunning manager and BTIG as co-manager. RxSight intends to use the proceeds for commercial expansion, international growth, product development, research and general corporate purposes.

Should I Sell My RXST Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of RxSight (NASDAQ:RXST) have gained 162.63% year to date. This compares to the average annual return of 55.93%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. RxSight stock currently has an RSI of 71.81, indicating overbought conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
RXST has a 52-week high of $66.54 and a 52-week low of $18.72.